The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
Open accessAbstract
Inflammatory signaling plays a key role in tumor progression, and the pleiotropic cytokine interleukin-6 (IL-6) is an important mediator of protumorigenic properties. Activation of the aryl hydrocarbon receptor (AHR) with exogenous ligands coupled with inflammatory signals can lead to synergistic induction of IL6 expression in tumor cells. Whether there are endogenous AHR ligands that can mediate IL6 production remains to be established. The indoleamine-2,3-dioxygenase pathway is a tryptophan oxidation pathway that is involved in controlling immune tolerance, which also aids in tumor escape. We screened the metabolites of this pathway for their ability to activate the AHR; results revealed that kynurenic acid (KA) is an efficient agonist for the human AHR. Structure-activity studies further indicate that the carboxylic acid group is required for significant agonist activity. KA is capable of inducing CYP1A1 messenger RNA levels in HepG2 cells and inducing CYP1A-mediated metabolism in primary human hepatocytes. In a human dioxin response element-driven stable reporter cell line, the EC(25) was observed to be 104nM, while in a mouse stable reporter cell line, the EC(25) was 10muM. AHR ligand competition binding assays revealed that KA is a ligand for the AHR. Treatment of MCF-7 cells with interleukin-1beta and a physiologically relevant concentration of KA (e.g., 100nM) leads to induction of IL6 expression that is largely dependent on AHR expression. Our findings have established that KA is a potent AHR endogenous ligand that can induce IL6 production and xenobiotic metabolism in cells at physiologically relevant concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression
Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727
Self-citationVeldhoen, M., Hirota, K., Christensen, J., O'Garra, A., & Stockinger, B. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081438 · Cited by 520
Association of the Ah receptor with the 90-kDa heat shock protein.
Perdew, G. H. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68314-0 · Cited by 509
Self-citationIndirubin and Indigo Are Potent Aryl Hydrocarbon Receptor Ligands Present in Human Urine
Adachi, J., Mori, Y., Matsui, S., Takigami, H., Fujino, J., Kitagawa, H., Miller, C. A., Kato, T., Saeki, K., & Matsuda, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100238200 · Cited by 407
Garrison, P. (1996) · Fundamental and Applied Toxicology · doi:10.1006/faat.1996.0056 · Cited by 405
Meyer, B. K., Pray-Grant, M. G., Vanden Heuvel, J. P., & Perdew, G. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.978 · Cited by 386
Self-citationActivation of the Ah Receptor Signal Transduction Pathway by Bilirubin and Biliverdin
Phelan, D., Winter, G. M., Rogers, W. J., Lam, J. C., & Denison, M. S. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0814 · Cited by 318
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
Cited by
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health
Cervenka, I., Agudelo, L. Z., & Ruas, J. L. (2017) · Science · doi:10.1126/science.aaf9794 · Cited by 1,382
Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
Self-citationLieu, E. L., Nguyen, T., Rhyne, S., & Kim, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0375-3 · Cited by 818
Denison, M. S., Soshilov, A. A., He, G., DeGroot, D. E., & Zhao, B. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr218 · Cited by 748
Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation
Hubbard, T. D., Murray, I. A., & Perdew, G. H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064246 · Cited by 640
Self-citationIL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.038 · Cited by 559
Aryl hydrocarbon receptor and intestinal immunity
Lamas, B., Natividad, J. M., & Sokol, H. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0019-2 · Cited by 516
The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective
Nigam, S. K., Bush, K. T., Martovetsky, G., Ahn, S.-Y., Liu, H. C., Richard, E., Bhatnagar, V., & Wu, W. (2015) · Physiological Reviews · doi:10.1152/physrev.00025.2013 · Cited by 502
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
The kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2022) · Inflammation Research · doi:10.1007/s00011-022-01598-8 · Cited by 432
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Inflammation, vitamin B6 and related pathways
Ueland, P. M., McCann, A., Midttun, Ø., & Ulvik, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.08.001 · Cited by 382
Wirthgen, E., Hoeflich, A., Rebl, A., & Günther, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01957 · Cited by 378
Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles
Hubbard, T. D., Murray, I. A., Bisson, W. H., Lahoti, T. S., Gowda, K., Amin, S. G., Patterson, A. D., & Perdew, G. H. (2015) · Scientific Reports · doi:10.1038/srep12689 · Cited by 377
Self-citationOmiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., & Peters, J. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 369
Self-citationAn expanding range of targets for kynurenine metabolites of tryptophan
Stone, T. W., Stoy, N., & Darlington, L. G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.006 · Cited by 344
(CONTAM), E. P. O. C. I. T. F. C., Knutsen, H. K., Alexander, J., Barregård, L., Bignami, M., Brüschweiler, B., Ceccatelli, S., Cottrill, B., Dinovi, M., Edler, L., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5333 · Cited by 342
Aryl Hydrocarbon Receptor Control of Adaptive Immunity
Quintana, F. J., & Sherr, D. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007823 · Cited by 329
The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment
Shinde, R., & McGaha, T. L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.010 · Cited by 329
Jin, U.-H., Lee, S.-O., Sridharan, G., Lee, K., Davidson, L. A., Jayaraman, A., Chapkin, R. S., Alaniz, R., & Safe, S. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.091165 · Cited by 327
Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1637 · Cited by 322
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Fujiwara, Y., Kato, S., Nesline, M. K., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102461 · Cited by 304
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0106-z · Cited by 274
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Stone, T. W., & Darlington, L. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12230 · Cited by 271
Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
Safe, S., Lee, S.-O., & Jin, U.-H. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft128 · Cited by 264
Obesity and cancer: existing and new hypotheses for a causal connection
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.022 · Cited by 262
Sallée, M., Dou, L., Cerini, C., Poitevin, S., Brunet, P., & Burtey, S. (2014) · Toxins · doi:10.3390/toxins6030934 · Cited by 255
Spiljar, M., Merkler, D., & Trajkovski, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01353 · Cited by 219
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Panda, S. K., Peng, V., Sudan, R., Ulezko Antonova, A., Di Luccia, B., Ohara, T. E., Fachi, J. L., Grajales-Reyes, G. E., Jaeger, N., Trsan, T., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.023 · Cited by 174
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Huang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138
“Immunosuppressive effect by activating AhR [37] 5.”
BackgroundMoffett, J. R., Arun, P., Puthillathu, N., Vengilote, R., Ives, J. A., Badawy, A. A.-B., & Namboodiri, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00031 · Cited by 89
AHR Ligands: Promiscuity in Binding and Diversity in Response
DeGroot, D., He, G., Fraccalvieri, D., Bonati, L., Pandini, A., & Denison, M. S. (2011) · The AH Receptor in Biology and Toxicology · doi:10.1002/9781118140574.ch4 · Cited by 43
Faber, S. C., Soshilov, A. A., Giani Tagliabue, S., Bonati, L., & Denison, M. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092692 · Cited by 36
Metadata
- Authors
- DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-01-27
- Volume
- 115
- Issue
- 1
- Pages
- 89-97
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2097615954
- Cited by
- 634
- References
- 40
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.